Lambros Chrones

449 total citations
20 papers, 314 citations indexed

About

Lambros Chrones is a scholar working on Pharmacology, Experimental and Cognitive Psychology and Psychiatry and Mental health. According to data from OpenAlex, Lambros Chrones has authored 20 papers receiving a total of 314 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pharmacology, 8 papers in Experimental and Cognitive Psychology and 8 papers in Psychiatry and Mental health. Recurrent topics in Lambros Chrones's work include Treatment of Major Depression (11 papers), Mental Health Research Topics (8 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (6 papers). Lambros Chrones is often cited by papers focused on Treatment of Major Depression (11 papers), Mental Health Research Topics (8 papers) and Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes (6 papers). Lambros Chrones collaborates with scholars based in United States, United Kingdom and Canada. Lambros Chrones's co-authors include Paula L. Jacobsen, Atul R. Mahableshwarkar, David S. Baldwin, George G. Nomikos, Elin Heldbo Reines, Ioana Florea, William Palo, Anita H. Clayton, Maëlys Touya and Thomas A. Macek and has published in prestigious journals such as Journal of Affective Disorders, Psychopharmacology and BMC Health Services Research.

In The Last Decade

Lambros Chrones

19 papers receiving 306 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lambros Chrones United States 7 204 120 110 69 42 20 314
Rocco de Filippis Italy 9 117 0.6× 46 0.4× 142 1.3× 55 0.8× 24 0.6× 30 327
Mélanie Brignone France 11 208 1.0× 118 1.0× 61 0.6× 59 0.9× 6 0.1× 21 323
Daniel L. Zimbroff United States 4 103 0.5× 150 1.3× 114 1.0× 56 0.8× 29 0.7× 5 436
Sebastian Ebert Denmark 4 107 0.5× 55 0.5× 71 0.6× 55 0.8× 7 0.2× 5 291
Hsin Chun Tsai Taiwan 12 41 0.2× 51 0.4× 115 1.0× 41 0.6× 23 0.5× 21 320
Ellen M. Richter United States 7 311 1.5× 129 1.1× 218 2.0× 38 0.6× 8 0.2× 10 407
S. Troy France 8 155 0.8× 104 0.9× 169 1.5× 37 0.5× 28 0.7× 15 313
Signe Hellmuth Denmark 4 107 0.5× 55 0.5× 70 0.6× 48 0.7× 7 0.2× 6 316
J. Søgaard Denmark 7 308 1.5× 198 1.6× 210 1.9× 49 0.7× 11 0.3× 9 448
Maxime Barakat Canada 8 207 1.0× 64 0.5× 103 0.9× 109 1.6× 63 1.5× 19 455

Countries citing papers authored by Lambros Chrones

Since Specialization
Citations

This map shows the geographic impact of Lambros Chrones's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lambros Chrones with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lambros Chrones more than expected).

Fields of papers citing papers by Lambros Chrones

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lambros Chrones. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lambros Chrones. The network helps show where Lambros Chrones may publish in the future.

Co-authorship network of co-authors of Lambros Chrones

This figure shows the co-authorship network connecting the top 25 collaborators of Lambros Chrones. A scholar is included among the top collaborators of Lambros Chrones based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lambros Chrones. Lambros Chrones is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Stephenson, Judith J., et al.. (2024). Antidepressant use and treatment-emergent sexual dysfunction among patients with major depressive disorder: Results from an internet-based survey study. Journal of Affective Disorders Reports. 16. 100750–100750. 1 indexed citations
3.
4.
Cormack, Francesca, Maggie McCue, Caroline Skirrow, et al.. (2023). Characterizing Longitudinal Patterns in Cognition, Mood, And Activity in Depression With 6-Week High-Frequency Wearable Assessment: Observational Study. JMIR Mental Health. 11. e46895–e46895. 4 indexed citations
5.
McDaniel, Brandon T., Victor P. Cornet, Lambros Chrones, et al.. (2023). Real-world clinical outcomes and treatment patterns in patients with MDD treated with vortioxetine: a retrospective study. BMC Psychiatry. 23(1). 938–938. 4 indexed citations
6.
Mattingly, Gregory W., et al.. (2023). Effectiveness of vortioxetine for major depressive disorder in real-world clinical practice: US cohort results from the global RELIEVE study. Frontiers in Psychiatry. 13. 977560–977560. 6 indexed citations
7.
8.
McCue, Maggie, et al.. (2023). User-Centered Design of a Digitally Enabled Care Pathway in a Large Health System: Qualitative Interview Study. JMIR Human Factors. 10. e42768–e42768. 2 indexed citations
9.
Ohayon, Maurice M., et al.. (2022). Longitudinal study to assess antidepressant treatment patterns and outcomes in individuals with depression in the general population. Journal of Affective Disorders. 321. 272–278. 3 indexed citations
10.
McIntyre, Roger S., Orly Lipsitz, Nelson B. Rodrigues, et al.. (2022). An App-Based Digit Symbol Substitution Test for Assessment of Cognitive Deficits in Adults With Major Depressive Disorder: Evaluation Study. JMIR Mental Health. 9(10). e33871–e33871. 3 indexed citations
11.
Touya, Maëlys, et al.. (2022). Incremental burden of relapse in patients with major depressive disorder: a real-world, retrospective cohort study using claims data. BMC Psychiatry. 22(1). 152–152. 13 indexed citations
12.
Larson, Sharon, et al.. (2021). Characterizing primary care for patients with major depressive disorder using electronic health records of a US-based healthcare provider. Journal of Affective Disorders. 300. 377–384. 4 indexed citations
13.
Touya, Maëlys, et al.. (2021). Incremental burden of comorbid major depressive disorder in patients with type 2 diabetes or cardiovascular disease: a retrospective claims analysis. BMC Health Services Research. 21(1). 778–778. 8 indexed citations
14.
Manjelievskaia, Janna, et al.. (2021). Adherence and persistence among patients with major depressive disorder enrolled in the vortioxetine tAccess Patient Support Program. Current Medical Research and Opinion. 37(8). 1385–1392. 3 indexed citations
15.
Ohayon, Maurice M., Maggie McCue, Andrew D. Krystal, et al.. (2021). A Longitudinal Study to Assess Antidepressant Treatment Patterns and Outcomes in Individuals with Depression in the General Population. CNS Spectrums. 26(2). 180–180. 1 indexed citations
16.
Baldwin, David S., Lambros Chrones, Ioana Florea, et al.. (2016). The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. Journal of Psychopharmacology. 30(3). 242–252. 138 indexed citations
17.
Tsai, Max, et al.. (2016). A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor. Psychopharmacology. 233(21-22). 3787–3795. 16 indexed citations
18.
Jacobsen, Paula L., et al.. (2015). Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder. International Clinical Psychopharmacology. 30(5). 255–264. 21 indexed citations
19.
Jacobsen, Paula L., et al.. (2015). Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction. The Journal of Sexual Medicine. 12(10). 2036–2048. 81 indexed citations
20.
Jacobsen, Paula L., et al.. (2014). P.2.f.022 Vortioxetine versus escitalopram in adults with well-treated major depressive disorder experiencing treatment-emergent sexual dysfunction. European Neuropsychopharmacology. 24. S464–S465. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Rocco de Filippis Breakdown of academic impact, for papers by Mélanie Brignone Breakdown of academic impact, for papers by Daniel L. Zimbroff Breakdown of academic impact, for papers by Sebastian Ebert Breakdown of academic impact, for papers by Hsin Chun Tsai Breakdown of academic impact, for papers by Ellen M. Richter Breakdown of academic impact, for papers by S. Troy Breakdown of academic impact, for papers by Signe Hellmuth Breakdown of academic impact, for papers by J. Søgaard Breakdown of academic impact, for papers by Maxime Barakat
Rankless by CCL
2026